ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: A comparison between mesothelioma and mesothelial cells

Journal of Cellular Physiology

Volumn 207, Issue 2, 2006, Pages 540-552

  Zhong, Jun ^a   Gencay, Mikael M Cornelsen ^b   Bubendorf, Lukas ^b   Burgess, Janette K ^a   Parson, Holly ^a   Robinson, Bruce W S ^c   Tamm, Michael ^b   Black, Judith L ^a   Roth, Michael ^a,b,d  

^a University of Sydney   (Australia)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; GELATINASE A; MATRIX METALLOPROTEINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; OLEOYL N HYDROXYLAMIDE; PLATELET DERIVED GROWTH FACTOR BB; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL CULTURE; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; MESOTHELIOMA; MESOTHELIUM CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE SECTION; ZYMOGRAPHY;

CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL CELLS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; MESOTHELIOMA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PLATELET-DERIVED GROWTH FACTOR; PROTEASE INHIBITORS; PROTEIN KINASE INHIBITORS; RNA, SMALL INTERFERING; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33645657833     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20605     Document Type: Article

References (45)

1. Attanoos RL, Griffin A, Gibbs AR. 2003. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 43:231-238.
2. Banerji A, Chakraborti J, Mitra A, Chatterjee A. 2005. Cell membrane-associated MT1-MMP-dependent activation of pro-MMP-2 in A375 melanoma cells. J Environ Pathol Toxicol Oncol 24:3-17.
3. Boyd PJ, Doyle J, Gee E, Pallan S, Haas TL. 2005. MAPK signaling regulates endothelial cell assembly into networks and expression of MT1-MMP and MMP-2. Am J Physiol Cell Physiol 288:C659-C668.
4. Carlin S, Resink TJ, Tamm M, Roth M. 2005. Urokinase signal transduction and its role in cell migration. FASEB J 19:195-202.
5. Curran S, Murray GI. 2000. Matrix metalloproteinases: Molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 36:1621-1630.
6. Dobra K, Nurminen M, Hjerpe A. 2003. Growth factors regulate the expression profile of their syndecan co-receptors and the differentiation of mesothelioma cells. Anticancer Res 23:2435-2444.
7. Donnini S, Morbidelli L, Taraboletti G, Ziehe M. 2004. ERK1-2 and p38 MAPK regulate MMP/TIMP balance and function in response to thrombospondin-1 fragments in the microvascular endothelium. Life Sci 74:2975-2985.
8. Dorai T, Kobayashi H, Holland JF, Ohnuma T. 1994. Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme. Mol Pharmacol 46:437-444.
9. Edwards JG, McLaren J, Jones JL, Waller DA, O'Byrne KJ. 2003. Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br J Cancer 88:1553-1559.
10. Eickelberg O, Kohler E, Reichenberger F, Bertschin S, Woodtli T, Erne P, Perruchoud AP, Roth M. 1999. Extracellular matrix depostion by primary human lung fibroblasts in response to TGF-β1 and TGF-β3. Am J Physiol 276:L814-L824.
11. Emmert-Buck MR, Roth MJ, Zhuang Z, Campo E, Rozhin J, Sloane BF, Liotta LA, Stetler-Stevenson WG. 1994. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am J Pathol 145:1285-1290.
12. Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL, Robinson BW. 1994. Transforming growth factor-beta: Antisense RNA-mediated inhibition affects anchorage-independent growth, tumourigenicity and tumour-infiltrating T-cells in malignant mesothelioma. Growth Factors 11:29-44.
13. Fitzpatrick DR, Peroni DJ, Bielefeldt-Ohmann H. 1995. The role of growth factors and cytokines in the tumourigenesis and immunobiology of malignant mesothelioma. Am J Respir Cell Mol Biol 12:455-460.
14. Garlepp MJ, Christmas TI, Manning LS, Mutsaers SE, Dench J, Leong C, Robinson BW. 1993. The role of platelet-derived growth factor in the growth of human malignant mesothelioma. Eur Respir Rev 3:189-191.
15. Gerwin BJ, Lechner JF, Reddel RR, Roberts AB, Robbins KC, Gabrielson EW. et al. 1987. Comparison of production of transforming growth factor-beta and platelet derived growth factor by normal mesothelial cells and mesothelioma cell lines. Cancer Res 47:6180-6184.
16. Giannelli G, Antonaci S. 2002. Gelatinases and their inhibitors in tumor metastasis: From biological research to medical applications. Histol Histopathol 17:339-345.
17. Giannelli G, Bergamini C, Marinosci F, Fransvea E, Quaranta M, Lupo L, Schiraldi O, Antonaci S. 2002. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 97:425-431.
18. Harvey P, Clark IM, Jaurand MC, Warn RM, Edwards DR. 2000. Hepatocyte growth factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br J Cancer 83:1147-1153.
19. Hernandez-Barrantes S, Shimura Y, Soloway PD, Sang QA, Fridman R. 2001. Differential roles of TIMP-4 and TIMP-2 in pro-MMP-2 activation by MT1-MMP. Biochem Biophys Res Commun 281:126-130.
20. Hirano H, Tsuji M, Kizaki T, Sashikata T, Yoshi Y, Okada Y, Mori H. 2002. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinase, collagens, and Ki67 antigen in pleural malignant mesothelioma: An immunohistochemical and electron microscopic study. Med Electron Microsc 35:16-23
21. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ. 2003. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 114:33-45.
22. Hughes RS. 2005. Malignant pleural mesothelioma. Am J Med Sci 329:29-44.
23. Jagirdar J, Lee TC, Reibman J, Gold LI, Aston C, Begin R, Rom WN. 1997. Immunohistochemical localization of transforming growth factor beta isoforms in asbestos-related diseases. Environ Health Perspect 5:1197-1203.
24. Kleiner DE, Stetler-Stevenson WG. 1994. Quantitative zymography: Detection of picogram quantities of gelatinases. Anal Biochem 218:325-329.
25. Klominek J, Baskin B, Hauzenberger D. 1998. Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction. Clin Exp Metastasis 16:529-539.
26. Lafleur MA, Handsley MM, Edwards DR. 2003. Metalloproteinases and their inhibitors in angiogenesis. Exp Rev Mol Med 5:1-39.
27. Langerak AW, De Laat PAJM, Van Der Linden-Van Beurden CAJ, Delahaye M, Van Der Kwast TH, Hoogsteden HC, Benner R, Versnel MA. 1996. Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. J Pathol 178:151-160.
28. Li H, Bauzon DE, Xu X, Tschesche H, Cao J, Sang QA. 1998. Immunological characterization of cell-surface and soluble forms of membrane type 1 matrix metalloproteinase in human breast cancer cells and in fibroblasts. Mol Carcinog 22:84-94.
29. Liu Z, Ivanoff A, Klominek J. 2001. Expression and activity of matrix metalloproteases in human malignant mesothelioma cell lines. Int J Cancer 91:638-643.
30. Maeda J, Ueki N, Ohkawa T, Iwahashi N, Nakano T, Hada T, Higashino K. 1994. Transforming growth factor-beta 1 (TGF-β1) and β2-like activities in malignant mesothelioma or primary lung cancer. Clin Exp Immunol 98:319-322.
31. Manning LS, Whitaker D, Murch AR, Garlepp MJ, Davis MR, Musk AW, Robinson BW. 1991. Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int J Cancer 47:285-290.
32. Munshi HG, Wu YI, Mukhopadhyay S, Ottaviano AJ, Sassano A, Koblinski JE, Platanias LC, Stack MS. 2004. Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta1-induced pericellular collagenolysis. J Biol Chem 279:39042-39050.
33. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL. 2002. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109:1551-1559.
34. Nagel H, Laskawi R, Wahlers A, Hemmerlein B. 2004. Expression of matrix metalloproteinases MP-2, MMP-9 and their tissue inhibitors TIMP-1, -2, and -3 in benign and malignant tumours of the salivary gland. Histopathology 44:222-231.
35. Overall CM, Wrana JL, Sodek J. 1991. Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J Biol Chem 266:14064-14071.
36. Papakonstantinou E, Karakiulakis G, Eickelberg O, Perruchoud AP, Block LH, Roth M. 1998. A 340-kDa hyaluronic acid secreted by human vascular smooth muscle cells regulates their proliferation and migration. Glycobiology 8:821-830.
37. Pierro E, Nicosia SV, Saunders B, Fultz CB, Nicosia RF, Mancuso S. 1996. Influence of growth factors on proliferation and morphogenesis of rabbit ovarian mesothelial cells in vitro. Biol Reprod 54:660-669.
38. Pistolesi M, Rusthoven J. 2004. Malignant pleural mesothelioma: Update, current management, and newer therapeutic strategies. Chest 126:1318-1329.
39. 2-agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 360:1293-1299.
40. Sabeh F, Ota I, Holmbeck K, Birkedal-Hansen H, Soloway P, Balbin M, Lopez-Otin C, Shapiro S, Inada M, Krane S, Allen E, Chung D, Weiss SJ. 2004. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol 167:769-781.
41. Sakata K, Shigemasa K, Nagai N, Ohama K. 2000. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 17:673-681.
42. Soulie P, Carrozzion F, Pepper MS, Strongin AY, Poupon MF, Montesano R. 2005. Membrane type-1 matrix metalloproteinase confers tumorigeneicity on non-malignant epithelial cells. Oncogene 24:1689-1697.
43. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. 1993. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Ann Rev Cell Biol 9:541-573.
44. Versnel MA, Claesson-Welsh L, Hammacher A. 1991. Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene 6:2005-2011.
45. Zellos L, Christiani DC. 2004. Epidemiology, biologic behavior, and natural history of mesothelioma. Thorac Surg Clin 14:469-477.